Skip to content

ADMA Biologics

US · ADMA #2705 by market cap Listed 1970
13.17 -0.17 -1.27%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 13.62 +2.10%
After-hours 13.30 +0.99%
Overnight 13.30 -0.30%
13.687.6013.172026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on ADMA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bullish
  • Recent price momentum is +7.7% on average (3-month/1-year).
  • Main-fund capital flow has been a net outflow over the last 45 sessions.
  • Short interest has fallen to 8.1% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Bullish
  • Price is above its 20-day average and above its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days E → D

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Factor grades

Ranked against 2848 U.S. stocks StockVane covers.

Last computed: 2026-11-22 02:27 UTC

Data coverage: 5 of 6 factors. Missing data is not a zero score.

Overall A-

The radar needs all six factors. Available grades are shown below.

Valuation C

How expensive the stock is versus earnings, sales and its own 5-year history.

P/E (TTM) 17.1x Better than 51%
Forward P/E 16.5x Better than 50%
Price / Sales 5.8x Better than 19%
P/E vs own 5-yr range 69th pctl Better than 39%
Growth N/A

How fast revenue, profit and free cash flow are compounding.

Not enough data to grade this factor.

Profitability A+

How much profit the business keeps from each dollar of sales and capital.

Gross margin 57.4% Better than 71%
Operating margin 37.5% Better than 94%
Net margin 28.8% Better than 89%
Return on equity 35.6% Better than 90%
Return on invested capital 30.6% Better than 96%
Momentum B

Recent price strength, skipping the latest month to avoid short-term noise.

3-month return 33.8% Better than 99%
6-month return 59.8% Better than 96%
12-month return (ex latest month) -37.8% Better than 6%
Distance below 52-week high 35.6% Better than 34%
Financial Health B+

Balance-sheet strength: leverage, liquidity and interest coverage.

Current ratio 6.7x Better than 90%
Debt to assets 12.8% Better than 66%
Interest coverage 26.7x Better than 85%
Free cash flow / net income 18.7% Better than 5%
Analyst View C+

What the Street thinks: share of Buy ratings and upside to the average target.

Analysts rating Buy 66.7% Better than 41%
Upside to average target 26.6% Better than 43%

Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.

Performance

1W -3.73%
1M +17.28%
3M +34.94%
6M +53.86%
YTD -27.80%
1Y -19.50%
3Y +226.80%
5Y +760.78%

Key statistics

Price & volume

Prev close
13.34
Open
13.26
Day range
13.10 - 13.47
Avg price
13.21
Volume
2.45M
Turnover
32.35M
Amplitude
2.77%
52-week range
7.21 - 20.46

Valuation

P/E
21.95
P/E (TTM)
17.10
P/B
6.66
EPS
0.60
Net profit
133.11M
Net assets
438.61M

Share structure

Market cap
2.92B
Float cap
2.70B
Shares out
221.85M
Float shares
205.22M

Dividend & listing

Dividend (TTM)
0.00
Listing date
1970-01-01
52-week range 45% of range
7.21 20.46

35.6% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

-16.80M net over the window

Short interest

Shares short
18.04M
As of
2026-10-30

Frequently asked questions

What is the current stock price of ADMA Biologics (ADMA)?

ADMA Biologics last traded at 13.17. This page shows a periodic quote snapshot. Check the displayed quote time.

What is ADMA Biologics's market cap?

About 2.92B.

What is the P/E ratio of ADMA Biologics?

The trailing twelve-month P/E is 17.10. The Valuation tab shows it against the stock's own five-year range.

Does ADMA Biologics pay a dividend?

ADMA Biologics does not currently pay a regular dividend.

Is ADMA Biologics a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 16.67, which implies 26.6% upside from the current price. This is not investment advice.

What is ADMA Biologics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates ADMA Biologics a D (Sell). Below its 200-day average or in the bottom third on momentum — the strategy is out of it. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

ADMA Biologics discussion 0 comments

Add a comment